Japan’s largest drugmaker working to develop Covid-19 treatment

TOKYO (Bloomberg): Takeda Pharmaceutical Co is developing an experimental therapy for the novel coronavirus or Covid-19 with the goal of making it available in 9 to 18 months, Japan’s largest drugmaker said.

"We will do all that we can to address the novel coronavirus threat, ” Dr Rajeev Venkayya, president of Takeda’s vaccine business unit and head of the response team, said in a statement Wednesday (March 4).